-
Product Insights
Plasma Cell Neoplasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Plasma Cell Neoplasm - Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMT-116 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMT-116 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMT-116 in Triple-Negative Breast Cancer (TNBC) Drug Details: AMT-116 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMT-116 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMT-116 in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMT-116 in Colorectal Cancer Drug Details: AMT-116 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMT-116 in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMT-116 in Cervical Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMT-116 in Cervical Cancer Drug Details: AMT-116 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMT-116 in Liver Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMT-116 in Liver Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMT-116 in Liver Cancer Drug Details: AMT-116 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMT-116 in Head And Neck Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMT-116 in Head And Neck Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMT-116 in Head And Neck Cancer Drug Details: AMT-116 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMT-116 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMT-116 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMT-116 in Pancreatic Cancer Drug Details: AMT-116 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMT-116 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMT-116 in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMT-116 in Gastric Cancer Drug Details: AMT-116 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMT-116 in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMT-116 in Bladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMT-116 in Bladder Cancer Drug Details: AMT-116 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMT-116 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMT-116 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMT-116 in Non-Small Cell Lung Cancer Drug Details: AMT-116 is...